Age-Related Eye Disease Study 2 (AREDS2) Reading Center

年龄相关眼病研究 2 (AREDS2) 阅读中心

• 批准号: 8740462
• 负责人: RONALD DANIS
• 金额: $ 74.96万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2014-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8740462
• 关键词: Accounting; Address; Adult; Adverse event; Advertising; Age related macular degeneration; Aging; Americas; Antioxidants; Area; Ascorbic Acid; Award; Behavioral; Beta Carotene; Bilateral; Biochemical; Blindness; Blood Vessels; Carotene; Cataract; Cataract Extraction; Characteristics; Chronic; Cicatrix; Clinic; Clinical; Clinical Research; Clinical Trials; Clinical Trials Data Monitoring Committees; Clinical Trials Design; Consumption; Contractor; Contracts; Contracts Review; Cost-Benefit Analysis; Cost-Benefit Data; Costs and Benefits; Country; Data Reporting; Development; Diagnostic Imaging; Diet; Disease; Dose; Drug Formulations; Drusen; Early Intervention; Elderly; Energy Metabolism; Enrollment; Ensure; Environmental Exposure; Etiology; European; Evaluation; Exhibits; Extramural Activities; Exudative age-related macular degeneration; Eye; Eye diseases; Funding; Fundus; Generations; Glaucoma; Goals; Image; Image Analysis; Imaging Techniques; Incidence; Intake; Lasers; Lens Opacities; Letters; Life; Light; Lutein; Measures; Metabolic; Monitor; Morphology; National Eye Institute; Nutrient; Odds Ratio; Omega-3 Fatty Acids; Operative Surgical Procedures; Oral; Outcome; Participant; Pathogenesis; Patients; Performance; Persons; Phase; Phase III Clinical Trials; Photochemotherapy; Placebos; Policies; Polyunsaturated Fatty Acids; Population; Population Study; Populations at Risk; Prevalence; Prevention; Preventive Intervention; Procedures; Process; Property; Protocols documentation; Publishing; Randomized Clinical Trials; Reading; Reporting; Research; Research Design; Retina; Retinal; Retinal Diseases; Risk; Signal Pathway; Site; Social Impacts; Source; Specific qualifier value; Structure of retinal pigment epithelium; Supplementation; System; Tissues; Training; Translating; Translational Research; United States; United States National Institutes of Health; Variant; Vision; Vision research; Visual Acuity; Vitamin E; Work; Xanthophylls; Zinc; age related; aged; base; clinical research site; comparative trial; compare effectiveness; data management; dehydroretinal; design; economic impact; effective therapy; eligible participant; end stage disease; evidence base; experience; geographic atrophy; healthy volunteer; image reconstruction; laser photocoagulation; macula; neovascular; protocol development; randomized trial; relating to nervous system; routine care; standard of care; zeaxanthin

AREDS 2 is a multi-center randomized trial of 4,000 participants designed to assess the effects of oral supplementation of high doses of macular xanthophylls (lutein and zeaxanthin) and omega-3 LCPUFAs (DHA and EPA) on the progression to advanced AMD. The study will enroll participants aged 50 to 85 years, with sufficiently clear ocular media to allow accurate assessment of AMD from fundus photographs. Participants should have either bilateral large drusen (>125 microns) or large drusen in one eye and advanced AMD in the fellow eye. All participants will be offered additional treatment with the original AREDS formulation (now considered standard of care) and 3 variations of this formula. These are: (1) no beta-carotene; (2) lower amounts of zinc; and (3) no beta-carotene and lower amounts of zinc. Eligible participants will be followed for a minimum of five years.

AREDS 2 是一项由 4,000 名参与者参与的多中心随机试验，旨在评估口服补充高剂量黄斑叶黄素（叶黄素和玉米黄质）和 omega-3 LCPUFA（DHA 和 EPA）对进展为晚期 AMD 的影响。该研究将招募年龄在 50 岁至 85 岁之间的参与者，他们拥有足够清晰的眼介质，可以通过眼底照片准确评估 AMD。参与者应有双侧大玻璃膜疣（>125 微米）或一只眼睛有大玻璃膜疣，而另一只眼睛有晚期 AMD。所有参与者都将接受原始 AREDS 配方（现在被视为护理标准）和该配方的 3 种变体的额外治疗。它们是：（1）不含β-胡萝卜素； (2) 锌含量较低； (3) 不含β-胡萝卜素和少量的锌。符合资格的参与者将被跟踪至少五年。